Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Myogen (MYOG) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (35)	4/10/2006 9:44:07 AM
From: tuck	Read Replies (2) \| Respond to of 50

Just when are we going to hear the 18 week safety data? Was the market expecting it, cuz it's acting disappointed, sending the stock down 5%? I see the efficacy results look weaker than those of ARIES-2, and I'm not sure what it means that the secondary endpoints are not stat sig but have good p-values. It would seem clinical worsening didn't occur much in the placebo group, either, which suggests relatively healthy patients in both arms. Anyone listen to the CC? I'm not going to have the time . . . TIA & Cheers, Tuck